Filing Flows › Arcus Biosciences (RCUS) › Q3 2026 › vs Q2 2026
Arcus Biosciences (RCUS) Q3 2026 vs Q2 2026 (quarter over quarter)
Arcus Biosciences's revenue fell $32.0M (-78%) from $41.0M in Q2 2026 to $9.0M in Q3 2026. The biggest changes: Other collaboration −$24.0M (-96%); License and development services −$8.0M (-50%).
Arcus Biosciences, Q3 2026: revenue $9.0M (-65% year over year), net loss $128M, operating cash flow −$88.0M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| License and development services | $8.0M | $16.0M | −$8.0M | -50% |
| Other collaboration | $1.0M | $25.0M | −$24.0M | -96% |
| Revenue | $9.0M | $41.0M | −$32.0M | -78% |
| Other income, net | $3.0M | $5.0M | −$2.0M | -40% |
| Net loss | $128M | $91.0M | $37.0M | +41% |
| Costs & expenses | $140M | $137M | $3.0M | +2% |
| Operating costs | $140M | $137M | $3.0M | +2% |
| Research & development | $117M | $113M | $4.0M | +4% |
| General & admin | $23.0M | $24.0M | −$1.0M | -4% |
| Operating cash sources | $128M | $91.0M | $37.0M | +41% |
| Depreciation & amortization | $2.0M | $3.0M | −$1.0M | -33% |
| Share-based compensation | $16.0M | $15.0M | $1.0M | +7% |
| Working capital & other | $22.0M | −$46.0M | $68.0M | — |
| Cash used in operations | $88.0M | $119M | −$31.0M | -26% |
| Net loss absorbed | $128M | $91.0M | $37.0M | +41% |
Questions
How much did Arcus Biosciences's revenue grow quarter over quarter in Q3 2026?
Arcus Biosciences's revenue fell $32.0M (-78%) from $41.0M in Q2 2026 to $9.0M in Q3 2026.
What drove Arcus Biosciences's revenue change in Q3 2026?
Other collaboration −$24.0M (-96%); License and development services −$8.0M (-50%).